Steroid carboline quaternary ammonium salt derivative, preparation method and application thereof, and antibacterial pharmaceutical composition

By synthesizing steroid carboline quaternary ammonium derivatives, the problems of antibiotic resistance and microbial infection are solved, effective inhibition of a variety of bacteria is achieved, and potential antibacterial drug components are demonstrated and the efficient preparation method is efficient.

CN118909017APending Publication Date: 2024-11-08CHANGZHI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410958961.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The use of existing antibiotics has led to increased bacterial resistance, the emergence of superbacteria poses a threat to human health, and existing antibacterial drugs are difficult to effectively deal with the increasingly serious microbial infection problem.

Method used

The steroid carboline quaternary ammonium derivative is designed to produce the target compound by reacting with tryptophan derived from different substituents and adding it to chlorinated hydrocarbons to form compounds with antibacterial activity, which are used to prepare antibacterial drugs.

Benefits of technology

Steroid carboline quaternary ammonium derivatives show significant inhibitory activity against a variety of pathogenic bacteria such as Solancroliella, Methicillin-resistant Staphylococcus aureus and Staphylococcus aureus, with MIC values ​​ranging from 0.5-32μg /mL, better than some control drugs, has the prospect of further research and development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The invention discloses a steroid carboline quaternary ammonium salt derivative as well as a preparation method and application thereof and an antibacterial pharmaceutical composition. The steroid carboline quaternary ammonium salt derivative provided by the invention has relatively good inhibitory activity on three pathogenic bacteria, namely, solanacearum, methicillin-resistant staphylococcus aureus and staphylococcus aureus; the preparation method provided by the invention is high in yield, the product is easy to separate, and the antibacterial activity of the steroid carboline quaternary ammonium salt derivative is superior to that of ampicillin sodium and equivalent to that of vancomycin, so that the steroid carboline quaternary ammonium salt derivative has a further research and development prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug synthesis, and relates to a steroidal carboline quaternary ammonium salt derivative, a preparation method and application thereof, and an antibacterial drug composition. Background Art

[0002] Bacterial infection not only poses a great threat to human health, but also causes losses to various economically valuable preparations. Bacterial infection has always been a focus of global public health, and the losses caused by bacterial infection are immeasurable. There are as many as 33 strains in the world that can pose a great threat to human survival. With the use of antibiotics, bacterial resistance has gradually become prominent, and the emergence of super bacteria has posed a greater challenge to human health. How to deal with the diseases caused by the increasingly severe microbial infections is still an urgent problem to be solved. The development of new antibacterial drugs is still an important means to deal with bacterial infections.

[0003] Based on the structure and physiological characteristics of carboline quaternary ammonium salt drugs, this study creatively designed and synthesized new steroidal carboline quaternary ammonium salt derivatives, and constructed a structurally diverse compound library using derivatization methods. The inhibitory activity against five pathogens, including Bacillus cereus, Bacillus subtilis, Ralstonia solanacearum, Methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus, was tested, and potential antibacterial candidate drugs were screened out. Summary of the invention

[0004] The purpose of the invention is to provide a steroidal carboline quaternary ammonium salt derivative, a preparation method and application thereof, and an antibacterial drug composition. The derivative provided by the invention exhibits good bacterial inhibition activity and can become a potential active ingredient for preparing antibacterial drugs. The invention also explores a high-yield synthesis route of the steroidal carboline quaternary ammonium salt derivative.

[0005] In order to achieve the above object, the technical solution provided by the present invention is as follows:

[0006] First, the present invention provides a steroidal carboline quaternary ammonium salt derivative, wherein the derivative has the following structure:

[0007] Wherein, the substituent R1 represents hydrogen, hydroxyl, ester group, halogen;

[0008] The substituents R2 and R3 represent hydroxyl, C1-C6 alkyl, hydroxyl-substituted C1-C6 alkyl, mono-substituted or poly-substituted aromatic group;

[0009] The substituent R4 represents a C1-C6 alkyl group or a benzyl group containing various substituents;

[0010] The substituent R5 represents hydrogen, methoxy or halogen.

[0011] In a preferred embodiment of the present invention, the substituent R4 is a C1-C6 straight-chain alkyl group, a C1-C6 branched-chain alkyl group, a monosubstituted or polysubstituted benzyl group, and a benzyl group substituted with various heteroatoms.

[0012] In an embodiment of the present invention, the derivative has the following structure:

[0013]

[0014]

[0015]

[0016] Secondly, the present invention provides a method for preparing the steroidal carboline quaternary ammonium salt derivative, comprising the following steps:

[0017] Step 1: Select steroidal aldehyde compound 1 as the synthetic intermediate of each steroidal carboline quaternary ammonium salt derivative, and react with tryptamine derived from different substituents under the catalysis of acetic acid to generate target derivative compound 2;

[0018] Step 2: Compound 2 is oxidized on palladium carbon to generate compound 3;

[0019] Step 3: Compound 3 is reacted with chlorohydrocarbons of different substitutions to obtain compound 4.

[0020] Third, the present invention also provides the use of steroidal carboline quaternary ammonium salt derivatives in the preparation of antibacterial drugs.

[0021] Preferably, the antibacterial drug is a drug that inhibits the activity of Ralstonia solanacearum, methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus.

[0022] Fourthly, the present invention provides an antibacterial pharmaceutical composition, comprising the steroidal carboline quaternary ammonium salt derivative of the present invention and a pharmaceutically acceptable excipient.

[0023] Furthermore, the dosage form of the pharmaceutical composition is granules, tablets, pills, dragees, suppositories, capsules, sustained-release capsules, sustained-release tablets, suspensions or injections.

[0024] Furthermore, the excipient is a pharmaceutical excipient for oral, enteral, parenteral or topical administration.

[0025] Furthermore, the auxiliary material is water, magnesium stearate, talc, starch, organic acid, dextran or lipid.

[0026] Beneficial effects of the present invention:

[0027] The steroidal carboline quaternary ammonium salt derivatives provided by the present invention have good inhibitory activity. Preliminary tests show that the MIC value of some of the antibacterial activities does not exceed 32 μg / mL. The preparation method of the derivatives provided by the present invention is also successfully applied for the first time in the synthesis of such compounds. The synthesis route is novel, the yield is high, and the product is easy to separate, which is the optimal route for preparing such compounds. The results of the embodiments of the present invention show that, with the antibacterial drugs ampicillin sodium and vancomycin as control drugs, the steroidal carboline quaternary ammonium salt derivatives provided by the present invention show good inhibitory activity against three pathogenic bacteria, Ralstonia solanacearum, Methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus, and the antibacterial activity of the steroidal carboline quaternary ammonium salt derivatives is better than that of ampicillin sodium, and is equivalent to that of vancomycin, and has a prospect for further research and development. DETAILED DESCRIPTION

[0028] The technical solution of the present invention is further described in detail below in conjunction with specific implementation methods.

[0029] The steroidal carboline quaternary ammonium salt derivatives of the present invention have the chemical structure of formula I:

[0030]

[0031] Wherein, the substituent R1 represents hydrogen, hydroxyl, ester group, halogen;

[0032] The substituents R2 and R3 represent hydroxyl, C1-C6 alkyl, hydroxyl-substituted C1-C6 alkyl, mono-substituted or poly-substituted aromatic group;

[0033] The substituent R4 represents a C1-C6 alkyl group or a benzyl group containing various substituents;

[0034] The substituent R5 represents hydrogen, methoxy or halogen.

[0035] Furthermore, the substituent R4 is preferably a C1-C6 straight-chain alkyl group, a C1-C6 branched-chain alkyl group, a monosubstituted or polysubstituted benzyl group, and a benzyl group substituted with various heteroatoms.

[0036] In order to describe the structure of the steroidal carboline quaternary ammonium salt derivative of formula (I) in detail, the present invention defines the terms used above and below.

[0037] The term "alkyl" shall refer to a monovalent group derived from any carbon atom of an alkane by removing a hydrogen atom. The carbon atoms of the "alkyl" form a straight chain or branched chain skeleton. Therefore, the "alkyl" can be divided into "straight chain alkyl" and "branched chain alkyl". The term includes primary, secondary and tertiary alkyl subclasses, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl and isohexyl. In particular, the term "alkane" refers to a saturated hydrocarbon compound containing only carbon and hydrogen.

[0038] The term "hydroxy-substituted C1-C6 alkyl" should be understood as a group in which one or more hydrogen atoms on the alkyl group are replaced by a hydroxyl group. "Hydroxy" should refer to the group -OH. For example, the hydrogen on the carbon 2 of the ethyl group is replaced by a hydroxyl group to form a 2-hydroxyethyl group.

[0039] The term "benzyl" may also be referred to as "phenylmethyl" and should include carbocyclic aromatic ring groups with carbon atoms ranging from C6 to C 10 Aromatic ring group.

[0040] The term "monosubstituted benzyl" should be understood as a benzyl group in which the hydrogen of one carbon atom is replaced by another group. For example, if the aromatic group of the benzyl is phenyl, the hydrogen can be replaced by halogen (fluorine, chlorine, bromine or iodine) to form o-, m- or p-halogenated benzyl; or methyl to form o-methylbenzyl, m-methylbenzyl or p-methylbenzyl; or methoxy to form o-methoxybenzyl, m-methoxybenzyl or p-methoxybenzyl. If the aromatic group is naphthylbenzyl, the reaction is similar and will not be described in detail here.

[0041] The term "polysubstituted benzyl" shall refer to a benzyl aromatic group in which two or more carbon atoms' hydrogen atoms are replaced by other groups. For example, if the benzyl group is a phenyl group, two chlorine atoms, or two fluorine atoms, or one chlorine atom and one fluorine atom can replace hydrogen atoms on different carbon atoms; the hydrogen on the benzene ring is replaced by two methyl groups to form 1,4-dimethylbenzyl. If the aromatic group is a naphthyl group, it is similar to this and will not be described in detail here.

[0042] The term "halogen" shall mean fluorine, chlorine, bromine or iodine.

[0043] The term "hydroxy" shall mean the group -OH.

[0044] The term "aldehyde group" shall mean the group -CHO.

[0045] The term "ester group" shall mean a -COO- group.

[0046] Furthermore, the present invention also provides some steroidal carboline quaternary ammonium salt derivatives of specific structures, such as compounds 4.1-4.27, all of which have substituents R1, R2, R3, R4, and R5 of formula (I). Substituents R1, R2, and R3 can replace hydrogen and hydroxyl groups; substituent R4 can represent methyl, ethyl, propyl, butyl, pentyl, benzyl, p-methylbenzyl, o-methylbenzyl, m-methylbenzyl, p-fluorobenzyl, o-fluorobenzyl, m-fluorobenzyl, p-chlorobenzyl, o-chlorobenzyl, m-chlorobenzyl, p-bromobenzyl, o-bromobenzyl, m-bromobenzyl, p-methoxybenzyl, o-methoxybenzyl, m-methoxybenzyl, p-trifluoromethylbenzyl, o-trifluoromethylbenzyl, m-trifluoromethylbenzyl, and p-trifluoromethoxybenzyl; substituents R1, R2, R3, and R4 are combined to form different compounds with different structures. Specifically:

[0047] Steroidal carboline quaternary ammonium salt derivative (Compound 4.1), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is o-methylbenzyl; R5 is methoxy.

[0048] Steroidal carboline quaternary ammonium salt derivative (Compound 4.2), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is p-methylbenzyl; R5 is methoxy.

[0049] Steroidal carboline quaternary ammonium salt derivative (Compound 4.3), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is m-methoxybenzyl; R5 is methoxy.

[0050] Steroidal carboline quaternary ammonium salt derivative (Compound 4.4), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is 3,5-dimethoxybenzyl; R5 is methoxy.

[0051] Steroidal carboline quaternary ammonium salt derivative (Compound 4.5), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is m-fluorobenzyl; R5 is methoxy.

[0052] Steroidal carboline quaternary ammonium salt derivative (Compound 4.6), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is o-fluorobenzyl; R5 is methoxy.

[0053] Steroidal carboline quaternary ammonium salt derivative (Compound 4.7), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is p-trifluoromethylbenzyl; R5 is methoxy.

[0054] Steroidal carboline quaternary ammonium salt derivative (Compound 4.8), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is p-trifluoromethoxybenzyl; R5 is methoxy.

[0055] Steroidal carboline quaternary ammonium salt derivative (Compound 4.9), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is ethylbenzyl; R5 is methoxy.

[0056] Steroidal carboline quaternary ammonium salt derivative (Compound 4.10), the substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is n-propylbenzyl; R5 is methoxy.

[0057] Steroidal carboline quaternary ammonium salt derivative (Compound 4.11), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is n-butylbenzyl; R5 is methoxy.

[0058] Steroidal carboline quaternary ammonium salt derivative (Compound 4.12), substituent R1 is hydroxyl; R2 and R3 are hydrogen; R4 is n-hexylbenzyl; R5 is methoxy.

[0059] Steroidal carboline quaternary ammonium salt derivative (Compound 4.13), substituents R1 and R2 are hydroxyl groups; R3 is hydrogen; R4 is o-methylbenzyl; and R5 is methoxy.

[0060] Steroidal carboline quaternary ammonium salt derivative (Compound 4.14), substituents R1 and R2 are hydroxyl groups; R3 is hydrogen; R4 is p-methylbenzyl; and R5 is methoxy.

[0061] Steroidal carboline quaternary ammonium salt derivative (Compound 4.15), substituents R1 and R2 are hydroxyl groups; R3 is hydrogen; R4 is m-methoxybenzyl; and R5 is methoxy.

[0062] Steroidal carboline quaternary ammonium salt derivative (Compound 4.16), substituents R1 and R2 are hydroxyl groups; R3 is hydrogen; R4 is 3,5-dimethoxybenzyl; and R5 is methoxy.

[0063] Steroidal carboline quaternary ammonium salt derivative (Compound 4.17), substituents R1 and R2 are hydroxyl groups; R3 is hydrogen; R4 is m-fluorobenzyl; and R5 is methoxy.

[0064] Steroidal carboline quaternary ammonium salt derivative (Compound 4.18), substituents R1 and R2 are hydroxyl groups; R3 is hydrogen; R4 is o-fluorobenzyl; and R5 is methoxy.

[0065] Steroidal carboline quaternary ammonium salt derivative (Compound 4.19), substituents R1 and R2 are hydroxyl groups; R3 is hydrogen; R4 is p-fluorobenzyl; and R5 is methoxy.

[0066] Steroidal carboline quaternary ammonium salt derivative (Compound 4.20), substituents R1 and R2 are hydroxyl groups; R3 is hydrogen; R4 is p-bromobenzyl; and R5 is methoxy.

[0067] Steroidal carboline quaternary ammonium salt derivative (Compound 4.21), substituents R1 and R2 are hydroxyl groups; R3 is hydrogen; R4 is p-trifluoromethoxybenzyl; and R5 is methoxy.

[0068] Steroidal carboline quaternary ammonium salt derivative (Compound 4.22), substituents R1 and R2 are hydroxyl groups; R3 is hydrogen; R4 is m-chlorobenzyl; and R5 is methoxy.

[0069] Steroidal carboline quaternary ammonium salt derivative (Compound 4.23), substituents R1, R2, R3 are hydroxyl groups; R4 is ethyl; R5 is methoxy.

[0070] Steroidal carboline quaternary ammonium salt derivative (Compound 4.24), substituents R1, R2, R3 are hydroxyl; R4 is n-propyl; R5 is methoxy.

[0071] Steroidal carboline quaternary ammonium salt derivative (Compound 4.25), substituents R1, R2, R3 are hydroxyl groups; R4 is n-butyl; R5 is methoxy group.

[0072] Steroidal carboline quaternary ammonium salt derivative (Compound 4.26), substituents R1, R2, R3 are hydroxyl groups; R4 is p-fluorobenzyl; R5 is methoxy.

[0073] Steroidal carboline quaternary ammonium salt derivative (Compound 4.27), substituents R1, R2, R3 are hydroxyl groups; R4 is p-methoxybenzyl; R5 is methoxy group.

[0074] In order to synthesize the steroidal carboline quaternary ammonium salt derivative having the structure of formula I, the present invention provides a preferred design synthesis route. The synthesis route comprises the following steps:

[0075] (a) selecting a steroidal aldehyde compound 1 as a synthetic intermediate of each steroidal carboline quaternary ammonium salt derivative, and reacting with tryptamines derived from different substituents under the catalysis of acetic acid to generate a target derivative compound 2;

[0076] (b) Compound 2 is oxidized on palladium carbon to generate compound 3;

[0077] (c) Compound 3 is reacted with chlorohydrocarbons of different substitutions to give compound 4.

[0078] The specific synthesis route is as follows:

[0079]

[0080] The above-mentioned steroidal carboline quaternary ammonium salt derivatives (Compound 2, Compound 3, Compounds 4.1-4.26) are all new compounds. The synthetic route recommended by the present invention is also successfully applied for the first time in the synthesis of such compounds. The synthetic route is novel, has high yield and the product is easy to separate. It can be said to be the best route for preparing such compounds. The specific synthetic method of the steroidal carboline quaternary ammonium salt derivative of formula (I) is described in detail in the examples.

[0081] The mechanism of action of these derivatives on living or in vitro tissues and organisms is still unclear, but the inventors surprisingly found that the steroidal carboline quaternary ammonium salt derivatives with the structure of formula (I) have good inhibitory activity against Ralstonia solanacearum, Methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus, and their MIC is between 0.5-32 μg / mL. Based on the above findings, the inventors preliminarily speculated that the steroidal carboline quaternary ammonium salt derivatives can be compatible with pharmaceutically acceptable excipients or carriers to prepare antibacterial drugs or pharmaceutical compositions. Preferably, the above antibacterial drugs or pharmaceutical compositions are used to inhibit the activity of Ralstonia solanacearum, Methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus. At the same time, the above discovery also inspired the inventors to further study the mechanism of action or target site of the synthesized steroidal carboline quaternary ammonium salt derivatives, and to try to prepare antibacterial drugs or pharmaceutical compositions.

[0082] In order to facilitate drug absorption or drug delivery to the target site, the antibacterial drug or pharmaceutical composition containing at least one steroidal carboline quaternary ammonium salt compound (or active ingredient) of the structure of formula (I) should also have a pharmaceutically acceptable excipient or carrier and be made into a suitable dosage form, such as granules, tablets, pills, dragees, suppositories, capsules, sustained-release capsules, sustained-release tablets, suspensions or injections. Pharmaceutically acceptable excipients or carriers, or excipients used in pharmaceutical preparations, such as water, magnesium stearate, talc, starch, organic acids, dextran or lipids, are pharmaceutical excipients suitable for oral, enteral, parenteral or topical administration.

[0083] Example 1

[0084] The chemical synthesis of the steroidal carboline quaternary ammonium salt derivative of formula I can be carried out according to the following steps.

[0085] (1) Dissolve 10 mmol of steroidal aldehyde 1 in a 250 mL eggplant-shaped flask containing 50 mL of ethanol and 50 mL of glacial acetic acid, and stir until completely dissolved; then add 5-methoxytryptamine (12 mmol) in batches and stir until dissolved; stir at room temperature for 0.5 h, and then react at 70°C for 12 hours. After the reaction is completed, the solvent is evaporated to dryness, and the crude product is separated by chromatography using petroleum ether: ethyl acetate = 2:1-3:1 to obtain the target product, and then dried to obtain the target compound 2.

[0086] (2) Compound 2 (10 mmol) was dissolved in 60 mL of toluene, and 100 mg of palladium carbon was added. After the addition, the reaction system was placed under reflux and stirred for 24 h. The reaction was checked to be complete. The target compound 3 was obtained by concentration under reduced pressure. The compound can be used directly in the next step without purification.

[0087] (3) Compound 3 (0.2 mmol) was dissolved in 10 mL of acetonitrile solution, and then a halogenated hydrocarbon (0.24 mmol) was added. The mixture was stirred under reflux for 6 hours. The reaction was detected to be complete, and the target compound 4 was obtained by column chromatography with petroleum ether: ethyl acetate = 1:1 to 5:1.

[0088] Example 2

[0089] The target compound and important intermediates synthesized in Example 1 were structurally identified. 1 H-NMR, 13 C-NMR.

[0090] Compound 4.1

[0091]

[0092] 1 H-NMR (CDCl3&CD3OD, 400MHz): δ8.40(s,2H),7.71(d,J=9.1Hz,1H),7.66(d,J=2.3Hz,1H),7.48-7.35(m,2H),7.20(t,J=8.5Hz,2H),7.05(t,J=7.7Hz ,1H),6.10-5.80(m,2H),3.93(s,3H),3.61-3.47(m,2H),3.40-3.21(m,1H ),1.98(d,J=11.4Hz,1H),1.13(d,J=6.4Hz,3H),0.89(s,3H),0.67(s,3H); 13 C-NMR(CDCl3&CD3OD,100MHz,two carbonmerged to others)δ156.3,144.7,140.7,135.7,133.2,132.7,132.3,131.7,129.7,127.7,125.7,124.9,121.0,116.4,114.7,103.0,71.7,58. 1,56.9,56.8,56.2,43.4,42.5,40.9,40.7,37.5,36.3,35.7,35.1,35.0,30.4,28.7,27.6,26.8,24.5,23.6,21.2,19.3,18.4,12.3.

[0093] Compound 4.2

[0094]

[0095] 1 H-NMR (CDCl3&CD3OD, 400MHz): δ8.47-8.28(m,2H),7.70(d,J=9.1Hz,1H),7.65(d,J=2.4Hz,1H),7.40(dd,J=9.1,2.5Hz,1H),7.20(d,J=7.8Hz,2H),7. 00(d,J=7.9Hz,2H),5.81(s,2H),3.93(s,3H),3.62-3.40(m,2H),3.23(t,J =13.0Hz,1H),2.33(s,3H),1.10(d,J=6.5Hz,3H),0.89(s,3H),0.65(s,3H); 13 C-NMR(CDCl3&CD3OD,100MHz,twocarbons merged to others)δ156.2,144.7,140.6,139.9,135.7,133.6,132.6,131.3,130.8,126.9,124.7,120.9,116.3,114.7,103.0,71.7,60.2,5 6.9,56.2,43.4,42.5,40.9,40.7,37.4,36.3,36.3,35.7,35.0,35.0,30.4,30.1,28.5,27.6,26.8,24.6,23.7,21.3,18.3,12.4.

[0096] Compound 4.3

[0097]

[0098] 11H-NMR (CDCl3 & CD3OD, 400 MHz): δ 8.40 (s, 2H), 7.72 (d, J = 9.1 Hz, 1H), 7.65 (d, J = 2.4 Hz, 1H), 7.38 (dd, J = 9.1, 2.4 Hz, 1H), 7.30 (t, J = 8.0 Hz, 1H), 6.90 (dd, J = 8.3, 2.4 Hz, 1H), 6.70 - 6.54 (m, 2H), 5.84 (s, 2H), 3.93 (s, 3H), 3.76 (s, 3H), 3.51 (d, J = 56.0 Hz, 2H), 3.30 - 3.16 (m, 1H), 1.09 (d, J = 6.4 Hz, 3H), 0.88 (s, 3H), 0.63 (s, 3H);

[0099] 13 13C-NMR (CDCl3 & CD3OD, 100 MHz) δ 161.0, 156.1, 144.8, 140.6, 135.9, 135.6, 133.8, 132.5, 131.3, 124.6, 120.9, 118.8, 116.3, 114.8, 114.4, 113.2, 103.0, 71.7, 60.2, 56.9, 56.9, 56.2, 55.7, 43.3, 42.5, 40.9, 40.7, 37.4, 36.3, 36.3, 35.7, 35.0, 35.0, 30.4, 28.5, 27.6, 27.6, 26.8, 24.5, 23.7, 21.2, 18.3, 12.3.

[0100] Compound 4.4

[0101]

[0102] 1 1H-NMR (CDCl3, 400 MHz): δ 14.29 (s, 1H), 8.11 (dd, J = 6.8, 2.3 Hz, 1H), 8.07 - 7.98 (m, 2H), 7.45 (s, 1H), 7.34 - 7.27 (m, 1H), 6.95 - 6.76 (m, 2H), 6.48 (s, 1H), 5.63 (q, J = 15.2 Hz, 2H), 3.91 (s, 3H), 3.75 (s, 3H), 3.72 - 3.49 (m, 6H), 1.14 (d, J = 6.6 Hz, 3H), 0.87 (s, 3H), 0.63 (s, 3H);

[0103] 1313C-NMR(CDCl3, 100 MHz) δ 155.3, 154.1, 150.9, 145.5, 140.9, 135.2, 130.9, 130.8, 123.4, 122.6, 119.9, 116.1, 115.8, 115.1, 114.8, 112.0, 101.9, 71.9, 56.7, 56.5, 56.0, 56.0, 54.9, 43.0, 42.2, 40.5, 40.3, 37.0, 36.6, 35.9, 35.5, 35.0, 34.7, 30.7, 29.8, 28.4, 27.7, 27.3, 26.5, 24.4, 23.5, 20.9, 18.5, 12.3.

[0104] Compound 4.5

[0105]

[0106] 1 1H-NMR(CDCl3 & CD3OD, 400 MHz): δ 8.44 (q, J = 6.6 Hz, 2H), 7.72 (d, J = 9.1 Hz, 1H), 7.67 (d, J = 2.4 Hz, 1H), 7.45 - 7.29 (m, 2H), 7.08 (td, J = 8.4, 2.4 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 6.83 (d, J = 9.1 Hz, 1H), 6.10 - 5.75 (m, 2H), 3.93 (s, 3H), 3.61 - 3.40 (m, 2H), 3.30 - 3.18 (m, 1H), 1.96 (d, J = 11.4 Hz, 1H), 1.09 (d, J = 6.4 Hz, 3H), 0.88 (s, 3H), 0.64 (s, 3H);

[0107] 1313C-NMR(CDCl3&CD3OD,100MHz)δ163.8(d,J=247.0Hz),156.2,144.7,140.7,137.1(d,J=8.0Hz),135.6,133.8,132.7,132.0(d,J=8.0Hz),124.8,122.5(d,J=3.0Hz),120.9,116.5,116.6(d,J=21.0Hz),114.8,114.0(d,J=22.0Hz),103.0,71.7,59.5,56.9,56.9,56.2,43.4,42.5,40.9,40.7,37.4,36.3,36.3,35.7,35.1,35.0,30.5,28.6,27.7,27.6,26.8,24.5,23.7,21.2,18.3,12.4.

[0108] Compound 4.6

[0109]

[0110] 1 1H-NMR(CDCl3&CD3OD,400MHz):δ8.40(s,2H),7.71(d,J=9.1Hz,1H),7.66(d,J=2.3Hz,1H),7.48-7.35(m,2H),7.20(t,J=8.5Hz,2H),7.05(t,J=7.7Hz,1H),6.10-5.80(m,2H),3.93(s,3H),3.61-3.47(m,2H),3.40-3.21(m,1H),1.98(d,J=11.4Hz,1H),1.13(d,J=6.4Hz,3H),0.89(s,3H),0.67(s,3H);

[0111] 1313C-NMR (CDCl3 & CD3OD, 100 MHz) δ 160.6 (d, J = 247.0 Hz), 156.2, 144.7, 140.7, 135.6, 133.4, 132.7, 132.2 (d, J = 8.0 Hz), 129.4 (d, J = 3.0 Hz), 126.0 (d, J = 4.0 Hz), 124.8, 121.6 (d, J = 14.0 Hz), 120.9, 116.8 (d, J = 21.0 Hz), 116.4, 114.8, 103.0, 71.7, 56.9, 56.2, 54.4, 54.3, 43.4, 42.6, 40.9, 40.7, 37.4, 36.3, 36.3, 35.8, 35.1, 35.0, 30.5, 28.6, 27.6, 27.5, 26.8, 24.6, 23.7, 21.3, 18.3, 12.4.

[0112] Compound 4.7

[0113]

[0114] 1 1H-NMR (CDCl3 & CD3OD, 400 MHz): δ 8.54 (d, J = 6.6 Hz, 1H), 8.48 (d, J = 6.6 Hz, 1H), 7.79 - 7.69 (m, 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.38 (dd, J = 9.0, 2.2 Hz, 1H), 7.30 (d, J = 8.1 Hz, 2H), 6.06 (s, 2H), 3.93 (s, 3H), 3.63 - 3.38 (m, 2H), 3.24 (t, J = 13.2 Hz, 1H), 1.95 (d, J = 12.6 Hz, 1H), 1.08 (d, J = 6.3 Hz, 3H), 0.88 (s, 3H), 0.62 (s, 3H);

[0115] 13C-NMR(CDCl3&CD3OD,100MHz)δ156.3,144.8,140.7,139.1,135.7,134.2,132.9,13 1.8(q,J=33.0Hz),127.5,127.0(q,J=4.0Hz),124.8,124.3(d,J=271.0Hz),121.0,1 16.8,114.8,103.2,71.8,59.7,57.1,56.9,56.3,43.4,42.6,41.0,40.8,37.4,36.4,36.4,35.8,35.1,35.0,30.5,28.6,27.9,27.7,26.9,24.5,23.7,21.3,18.3,12.4.

[0116] Compound 4.8

[0117]

[0118] 1 H-NMR (CDCl3, 400MHz): δ13.10(s,1H),8.55(d,J=6.6Hz,1H),8.29(d,J=6.5Hz,1H),7.96(d,J=9.0Hz,1H),7.54(d,J=2.3Hz,1H),7 .24-7.02(m,5H),6.25-5.73(m,2H),3.88(s,3H),3.67-3.32(m,3H),2.63(s,1H),1.03(d,J=6.1Hz,3H),0.79(s,3H),0.49(s,3H);

[0119] 13 C-NMR(CDCl3,100MHz)δ155.4,149.6,144.6,140.3,134.9,133.2,132.9,1 31.3,128.5,123.8,121.8,120.3(q,J=257.0Hz),120.1,116.0,115.3,102. 3,71.6,58.7,56.5,56.3,56.1,42.8,42.0,40.3,40.1,36.7,36.3,35.7,35.3,34.9,34.5,30.6,28.1,27.9,27.1,26.4,24.1,23.3,20.7,18.5,12.1.

[0120] Compound 4.9

[0121]

[0122] 1 1H-NMR (CDCl3, 400 MHz): δ 13.01 (s, 1H), 8.49 (d, J = 6.6 Hz, 1H), 8.27 (d, J = 6.5 Hz, 1H), 7.93 (d, J = 9.0 Hz, 1H), 7.50 (d, J = 2.3 Hz, 1H), 7.16 (dd, J = 9.0, 2.5 Hz, 1H), 4.67 (q, J = 7.3 Hz, 2H), 3.86 (s, 3H), 3.70 - 3.53 (m, 2H), 3.52 - 3.36 (m, 1H), 2.68 (s, 1H), 1.63 (t, J = 7.2 Hz, 3H), 1.12 (d, J = 6.2 Hz, 3H), 0.79 (s, 3H), 0.56 (s, 3H);

[0123] 13 13C-NMR (CDCl3, 100 MHz) δ 155.2, 143.5, 139.9, 134.8, 131.8, 130.9, 123.2, 120.0, 116.3, 115.2, 102.3, 71.5, 56.4, 56.3, 56.1, 51.5, 42.9, 42.0, 40.3, 40.1, 36.9, 36.3, 35.7, 35.4, 35.2, 34.5, 30.5, 28.4, 27.3, 27.1, 26.4, 24.2, 23.4, 20.8, 18.6, 17.4, 12.2.

[0124] Compound 4.10

[0125]

[0126] 1 1H-NMR (CDCl3, 400 MHz): δ 13.18 (s, 1H), 8.49 (d, J = 6.6 Hz, 1H), 8.26 (d, J = 6.5 Hz, 1H), 7.99 (d, J = 9.1 Hz, 1H), 7.50 (d, J = 2.4 Hz, 1H), 7.21 (dd, J = 9.1, 2.3 Hz, 1H), 4.57 (t, J = 7.7 Hz, 2H), 3.88 (s, 3H), 3.68 - 3.44 (m, 3H), 2.40 (s, 1H), 2.00 (q, J = 7.7 Hz, 2H), 1.14 (d, J = 6.2 Hz, 3H), 1.06 (t, J = 7.4 Hz, 3H), 0.82 (s, 3H), 0.59 (s, 3H);

[0127] 13C-NMR (CDCl3, 100MHz) δ155.3,143.7,140.2,135.0,132.2,131.0,123.3,120.1,115.9,115.4,102.2,71.6,57.6,56.5,56.4,56.1 ,42.9,42.0,40.4,40.2,36.8,36.4,35.8,35.4,35.3,34.6,30.6,28.5,27.3,27.2,26.4,25.5,24.2,23.4,20.8,18.7,12.2,11.1.

[0128] Compound 4.11

[0129]

[0130] 1 H-NMR (CDCl3, 400MHz): δ13.24 (s, 1H), 8.43 (d, J = 6.6Hz, 1H), 8.26 (d, J = 6.5 Hz,1H),7.99(d,J=9.1Hz,1H),7.50(d,J=2.4Hz,1H),7.21(dd,J=9.1,2.4Hz, 1H),4.58(t,J=7.9Hz,2H),3.88(s,3H),3.58(dt,J=10.7,4.7Hz,3H),2.29(s ,1H),1.15(d,J=6.2Hz,3H),0.99(t,J=7.5Hz,3H),0.83(s,3H),0.60(s,3H); 13 C-NMR (CDCl3, 100MHz) δ155.3,143.8,140.2,135.0,132.1,131.0,123.3,120.1,116.0,115.5,102.2,71.7,56.5,56.4,56.2,56.1,43 .0,42.1,40.4,40.2,36.9,36.4,35.8,35.4,35.3,34.6,34.1,30.6,28.5,27.4,27.2,26.4,24.3,23.4,20.8,20.0,18.7,13.7,12.2.

[0131] Compound 4.12

[0132]

[0133] 1H-NMR(CDCl3, 400 MHz): δ 13.10 (s, 1H), 8.46 (d, J = 6.6 Hz, 1H), 8.26 (d, J = 6.5 Hz, 1H), 7.97 (d, J = 9.0 Hz, 1H), 7.50 (d, J = 2.4 Hz, 1H), 7.19 (dd, J = 9.1, 2.4 Hz, 1H), 4.56 (t, J = 7.8 Hz, 2H), 3.87 (s, 3H), 3.69 - 3.36 (m, 3H), 1.14 (d, J = 6.2 Hz, 3H), 0.84 (t, J = 7.0 Hz, 3H), 0.81 (s, 3H), 0.59 (s, 3H);

[0134] 13 C-NMR(CDCl3, 100 MHz) δ 155.2, 143.6, 140.2, 135.0, 132.1, 130.9, 123.2, 120.0, 116.0, 115.4, 102.2, 71.6, 56.5, 56.4, 56.3, 56.0, 42.9, 42.0, 40.4, 40.2, 36.9, 36.4, 35.8, 35.4, 35.3, 34.5, 32.2, 31.3, 30.5, 28.5, 27.3, 27.2, 26.4, 26.2, 24.2, 23.4, 22.5, 20.8, 18.6, 14.0, 12.2.

[0135] Compound 4.13

[0136]

[0137] 1 H-NMR(CD3OD & CDCl3, 400 MHz): δ 8.41 (d, J = 6.5 Hz, 1H), 8.25 (d, J = 6.6 Hz, 1H), 7.75 (d, J = 9.1 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.40 (dd, J = 9.1, 2.4 Hz, 1H), 7.34 - 7.22 (m, 2H), 7.16 - 7.06 (m, 1H), 6.33 (d, J = 7.8 Hz, 1H), 5.85 (d, J = 3.6 Hz, 2H), 3.99 - 3.85 (m, 4H), 3.59 - 3.35 (m, 2H), 3.27 - 3.09 (m, 2H), 2.42 (s, 3H), 1.13 (d, J = 5.9 Hz, 3H), 0.87 (s, 3H), 0.66 (s, 3H);

[0138] 1313C-NMR (CD3OD & CDCl3, 100 MHz) δ 156.1, 144.8, 140.6, 135.7, 135.5, 133.3, 132.5, 132.5, 131.6, 129.5, 127.6, 125.7, 124.6, 120.9, 116.5, 114.8, 103.0, 73.3, 71.7, 58.1, 56.2, 48.4, 47.3, 47.0, 42.6, 37.4, 36.4, 35.7, 34.9, 34.6, 33.9, 30.1, 29.0, 28.0, 27.6, 27.3, 26.6, 24.1, 23.4, 19.3, 17.2, 13.0, 9.0.

[0139] Compound 4.14

[0140]

[0141] 1 1H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.38 (s, 2H), 7.69 (d, J = 9.1 Hz, 1H), 7.66 (d, J = 2.4 Hz, 1H), 7.40 (dd, J = 9.1, 2.4 Hz, 1H), 7.19 (d, J = 7.8 Hz, 2H), 7.01 (d, J = 7.8 Hz, 2H), 5.95 - 5.72 (m, 2H), 3.97 (s, 1H), 3.93 (s, 3H), 3.58 - 3.41 (m, 1H), 3.29 - 3.19 (m, 1H), 2.32 (s, 3H), 1.15 (d, J = 5.8 Hz, 3H), 0.88 (s, 3H), 0.67 (s, 3H);

[0142] 13 13C-NMR (CD3OD & CDCl3, 100 MHz) δ 156.1, 144.8, 140.6, 139.9, 135.6, 133.6, 132.5, 131.4, 130.7, 126.9, 124.6, 120.9, 116.3, 114.7, 102.9, 73.4, 71.7, 60.2, 56.2, 48.4, 47.5, 47.0, 42.6, 37.3, 36.4, 36.3, 35.7, 34.8, 34.6, 33.9, 30.1, 29.0, 27.9, 27.6, 27.4, 26.6, 24.2, 23.4, 21.3, 17.0, 13.0.

[0143] Compound 4.15

[0144]

[0145] 1 1H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.46 (d, J = 1.9 Hz, 2H), 7.77 (d, J = 9.1 Hz, 1H), 7.71 (d, J = 2.4 Hz, 1H), 7.44 (dd, J = 9.1, 2.4 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 6.94 (dd, J = 8.4, 2.4 Hz, 1H), 6.74 - 6.64 (m, 2H), 6.04 - 5.78 (m, 2H), 4.02 (t, J = 2.8 Hz, 1H), 3.99 (s, 3H), 3.84 - 3.78 (m, 3H), 3.63 - 3.46 (m, 2H), 3.40 - 3.14 (m, 2H), 1.20 (d, J = 6.1 Hz, 3H), 0.93 (s, 3H), 0.72 (s, 3H);

[0146] 13 13C-NMR (CD3OD & CDCl3, 100 MHz) δ 160.9, 156.0, 144.8, 140.5, 135.9, 135.5, 133.8, 132.5, 131.2, 124.6, 120.8, 118.8, 116.3, 114.7, 114.3, 113.2, 103.0, 73.3, 71.7, 60.2, 56.2, 55.7, 48.4, 47.4, 47.0, 42.5, 37.3, 36.4, 35.7, 34.8, 34.6, 33.9, 30.1, 29.0, 27.9, 27.5, 27.4, 26.6, 24.1, 23.4, 17.1, 13.0, 9.0.

[0147] Compound 4.16

[0148]

[0149] 11H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.29 (d, J = 6.6 Hz, 1H), 8.22 (d, J = 6.7 Hz, 1H), 7.71 (d, J = 9.0 Hz, 1H), 7.61 (d, J = 2.4 Hz, 1H), 7.40 (dd, J = 9.1, 2.5 Hz, 1H), 7.02 - 6.86 (m, 2H), 6.50 (s, 1H), 5.87 - 5.63 (m, 2H), 3.98 (t, J = 2.9 Hz, 1H), 3.92 (s, 3H), 3.77 (s, 3H), 3.70 (s, 3H), 3.61 - 3.47 (m, 2H), 3.35 - 3.09 (m, 2H), 1.18 (d, J = 5.9 Hz, 3H), 0.88 (s, 3H), 0.70 (s, 3H);

[0150] 13 13C-NMR (CD3OD & CDCl3, 100 MHz) δ 156.0, 154.4, 151.3, 144.9, 140.5, 135.4, 132.7, 132.2, 124.5, 122.8, 120.8, 116.1, 115.9, 114.9, 114.7, 112.4, 102.8, 73.3, 71.7, 56.2, 56.1, 56.0, 55.7, 47.3, 47.0, 46.8, 42.5, 37.4, 36.3, 36.3, 35.7, 34.7, 34.5, 33.9, 30.1, 29.0, 28.0, 27.5, 27.1, 26.6, 24.1, 23.4, 17.0, 13.0.

[0151] Compound 4.17

[0152]

[0153] 1 1H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.49 (q, J = 6.6 Hz, 2H), 7.76 (d, J = 9.1 Hz, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.47 - 7.37 (m, 2H), 7.11 (td, J = 8.4, 2.1 Hz, 1H), 6.95 (d, J = 7.8 Hz, 1H), 6.88 (d, J = 9.2 Hz, 1H), 5.97 (s, 2H), 4.01 (t, J = 2.8 Hz, 1H), 3.98 (s, 3H), 3.75 - 3.58 (m, 1H), 3.56 - 3.45 (m, 2H), 3.38 - 3.24 (m, 1H), 1.19 (d, J = 6.4 Hz, 3H), 0.92 (s, 3H), 0.71 (s, 3H).;

[0154] 13 13C-NMR (CD3OD & CDCl3, 100 MHz) δ 163.8 (d, J = 248.0 Hz), 156.1, 144.8, 140.6, 137.1 (d, J = 7.0 Hz), 135.6, 133.8, 132.6, 131.9 (d, J = 9.0 Hz), 124.8, 122.6 (d, J = 3.0 Hz), 120.9, 116.5, 116.4 (d, J = 21.0 Hz), 114.7, 114.0 (d, J = 23.0 Hz), 103.0, 73.3, 71.7, 59.5, 56.2, 48.4, 47.4, 47.0, 42.6, 37.3, 36.4, 36.3, 35.7, 34.9, 34.6, 33.9, 30.1, 29.0, 28.0, 27.6, 27.4, 26.6, 24.1, 23.4, 17.1, 13.0.

[0155] Compound 4.18

[0156]

[0157] 1 1H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.39 (s, 2H), 7.71 (d, J = 9.1 Hz, 1H), 7.65 (d, J = 2.2 Hz, 1H), 7.47 - 7.33 (m, 2H), 7.25 - 7.14 (m, 2H), 7.07 (t, J = 7.2 Hz, 1H), 6.09 - 5.83 (m, 2H), 3.98 (s, 1H), 3.93 (s, 3H), 3.62 - 3.43 (m, 2H), 3.38 - 3.24 (m, 1H), 1.18 (d, J = 6.5 Hz, 3H), 0.88 (s, 3H), 0.69 (s, 3H);

[0158] 1313C-NMR(CD3OD & CDCl3, 100 MHz) δ 160.6 (d, J = 246.0 Hz), 156.1, 144.8, 140.6, 135.5, 133.3, 132.5, 132.2 (d, J = 8.0 Hz), 129.5 (d, J = 3.0 Hz), 125.9 (d, J = 3.0 Hz), 124.7, 121.6 (d, J = 14.0 Hz), 120.9, 116.8 (d, J = 21.0 Hz), 116.4, 114.7, 102.9, 73.3, 71.7, 56.2, 54.4 (d, J = 4.0 Hz), 48.4, 47.4, 47.0, 42.5, 37.3, 36.4, 36.3, 35.7, 34.9, 34.6, 33.9, 30.1, 29.0, 28.0, 27.6, 27.2, 26.6, 24.1, 23.4, 17.1, 13.0.

[0159] Compound 4.19

[0160]

[0161] 1 1H-NMR(CD3OD & CDCl3, 400 MHz): δ 8.39 (q, J = 6.6 Hz, 2H), 7.71 (d, J = 9.1 Hz, 1H), 7.63 (d, J = 2.1 Hz, 1H), 7.38 (dd, J = 9.1, 2.3 Hz, 1H), 7.18 - 7.12 (m, 2H), 7.08 (t, J = 8.5 Hz, 2H), 5.87 (d, J = 3.4 Hz, 2H), 3.96 (t, J = 2.7 Hz, 1H), 3.92 (s, 3H), 3.59 - 3.41 (m, 2H), 3.32 - 3.23 (m, 1H), 1.15 (d, J = 6.3 Hz, 2H), 0.87 (s, 3H), 0.67 (s, 3H);

[0162] 1313C-NMR (CD3OD & CDCl3, 100 MHz, one carbon merged to others) δ 163.4 (d, J = 247.0 Hz), 155.9, 144.7, 140.8, 135.7, 133.3, 132.4, 130.4 (d, J = 3.0 Hz), 129.1 (d, J = 8.0 Hz), 124.5, 120.8, 117.0 (d, J = 22.0 Hz), 116.3, 114.8, 102.8, 73.3, 71.7, 59.3, 56.2, 48.3, 47.3, 47.0, 42.5, 37.2, 36.3, 35.6, 34.9, 34.5, 33.8, 30.1, 28.9, 27.9, 27.5, 27.2, 26.5, 24.0, 23.3, 17.0, 13.0.

[0163] Compound 4.20

[0164]

[0165] 1 1H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.41 (d, J = 6.6 Hz, 1H), 8.35 (d, J = 6.6 Hz, 1H), 7.68 (d, J = 9.1 Hz, 1H), 7.59 (d, J = 2.4 Hz, 1H), 7.46 (d, J = 8.2 Hz, 2H), 7.34 (dd, J = 9.1, 2.4 Hz, 1H), 6.99 (d, J = 8.3 Hz, 2H), 5.95 - 5.70 (m, 2H), 3.91 (s, 1H), 3.89 (s, 3H), 3.67 - 3.36 (m, 3H), 3.26 - 3.11 (m, 1H), 1.10 (d, J = 5.3 Hz, 3H), 0.83 (s, 3H), 0.62 (s, 3H);

[0166] 13 13C-NMR (CD3OD & CDCl3, 100 MHz, one carbon merged to others) δ 156.0, 144.7, 140.5, 135.4, 133.6, 133.6, 133.0, 132.4, 128.6, 124.6, 123.6, 120.7, 116.3, 114.7, 102.8, 73.3, 71.7, 59.6, 56.2, 48.2, 47.3, 46.9, 42.4, 37.2, 36.3, 35.6, 34.7, 34.5, 33.8, 30.0, 28.8, 27.9, 27.5, 27.3, 26.5, 24.1, 23.3, 17.0, 13.0.

[0167] Compound 4.21

[0168]

[0169] 1 H-NMR (CD3OD&CDCl3,400MHz): δ8.47(d,J=6.6Hz,1H),8.41(d,J=6.5Hz,1H),7.7 2(d,J=9.0Hz,1H),7.65(d,J=2.4Hz,1H),7.38(dd,J=9.1,2.5Hz,1H),7.28-7.15 (m,4H),6.07-5.85(m,2H),3.96(s,1H),3.92(s,3H),3.58-3.40(m,2H),3.35-3. 23(m,1H),3.15(q,J=7.3Hz,1H),1.15(d,J=6.3Hz,3H),0.87(s,3H),0.66(s,3H);

[0170] 13 C-NMR(CD3OD&CDCl3,100MHz)δ156.1,150.0(d,J=2.0Hz),144.6,140.5,135.5, 133.7,133.3,132.5,128.7,124.7,122.3,120.8,120.7(q,J=256.0Hz),116.5,1 14.7,102.9,73.3,71.7,59.2,56.2,48.3,47.3,47.0,42.5,37.2,36.3,35.7,34.9,34.5,33.9,30.1,28.9,28.0,27.5,27.4,26.5,24.0,23.3,17.1,13.0,8.9.

[0171] Compound 4.22

[0172]

[0173] 11H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.42 (q, J = 6.6 Hz, 2H), 7.72 (d, J = 9.1 Hz, 1H), 7.65 (d, J = 2.4 Hz, 1H), 7.40 (dd, J = 9.1, 2.4 Hz, 1H), 7.34 (d, J = 4.5 Hz, 2H), 7.11 (s, 1H), 7.02 (d, J = 4.7 Hz, 1H), 5.91 (s, 2H), 3.96 (s, 1H), 3.93 (s, 3H), 3.74 - 3.40 (m, 3H), 3.30 - 3.16 (m, 1H), 1.14 (d, J = 6.1 Hz, 3H), 0.87 (s, 3H), 0.67 (s, 3H);

[0174] 13 13C-NMR (CD3OD & CDCl3, 100 MHz, one carbon merged to others) δ 156.1, 144.7, 140.6, 136.6, 136.0, 135.5, 133.7, 132.5, 131.4, 129.7, 126.9, 125.0, 124.7, 120.8, 116.4, 114.7, 102.9, 73.3, 71.7, 59.4, 56.2, 48.3, 47.3, 47.0, 42.5, 37.2, 36.3, 35.6, 34.8, 34.5, 33.8, 30.1, 28.9, 27.9, 27.5, 27.4, 26.5, 24.0, 23.3, 17.0, 13.0.

[0175] Compound 4.23

[0176]

[0177] 1 1H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.44 - 8.28 (m, 2H), 7.69 (d, J = 9.1 Hz, 1H), 7.62 (d, J = 2.3 Hz, 1H), 7.38 (dd, J = 9.0, 2.3 Hz, 1H), 4.78 - 4.59 (m, 2H), 3.99 (s, 1H), 3.92 (s, 3H), 3.78 (d, J = 3.3 Hz, 1H), 3.51 (td, J = 13.7, 13.2, 5.0 Hz, 1H), 3.43 - 3.23 (m, 1H), 2.22 - 2.05 (m, 2H), 1.68 (t, J = 7.1 Hz, 3H), 1.24 (d, J = 6.6 Hz, 3H), 0.87 (s, 3H), 0.73 (s, 3H);

[0178] 13 C-NMR (CD3OD&CDCl3,100MHz)δ156.0,143.7,140.2,135.4,132.2,132.1,124.3,120.8,116.6,114.6,102.9,73.4,71.9,68.5,56.2 ,52.2,47.0,47.0,42.1,41.9,39.7,39.5,37.3,35.7,35.3,35.1,34.9,30.2,28.5,28.2,26.8,26.6,23.6,22.7,17.4,17.3,12.8.

[0179] Compound 4.24

[0180]

[0181] 1 H-NMR (CD3OD&CDCl3,400MHz): δ8.64-8.30(m,2H),7.74(d,J=2.5Hz,1H),7.68(d,J=9.1 Hz,1H),7.41(dd,J=9.1,2.5Hz,1H),4.66-4.50(m,2H),4.02(d,J=2.8Hz,1H),3.84-3.7 2(m,1H),3.52(td,J=14.0,5.1Hz,1H),3.44-3.32(m,2H),2.20(d,J=37.7Hz,2H),2.08( q,J=7.5Hz,2H),1.28(d,J=6.5Hz,3H),1.11(t,J=7.4Hz,3H),0.91(s,3H),0.77(s,3H);

[0182] 13 C-NMR (CD3OD&CDCl3,100MHz)δ156.5,144.3,140.6,135.9,133.4,132.7,124.6,121.4,116.8,114.7,103.4,73.7,72.3,68.7,58.7,5 6.3,47.7,47.3,42.6,42.5,40.3,40.0,37.8,36.1,35.6,35.5,35.5,30.7,29.1,28.6,27.4,27.1,26.1,23.9,23.0,17.5,13.0,11.2.

[0183] Compound 4.25

[0184]

[0185] 1 1H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.34 (s, 2H), 7.66 (d, J = 9.1 Hz, 1H), 7.62 (d, J = 2.4 Hz, 1H), 7.33 (dd, J = 9.1, 2.5 Hz, 1H), 4.05 - 3.94 (m, 1H), 3.88 (s, 3H), 3.75 (d, J = 3.2 Hz, 1H), 3.47 (td, J = 13.4, 13.0, 5.3 Hz, 1H), 3.39 - 3.14 (m, 1H), 2.22 - 2.04 (m, 2H), 2.03 - 1.93 (m, 2H), 1.22 (d, J = 6.3 Hz, 3H), 0.99 (t, J = 7.3 Hz, 3H), 0.84 (s, 3H), 0.71 (s, 3H);

[0186] 13 13C-NMR (CD3OD & CDCl3, 100 MHz) δ 156.2, 143.9, 140.4, 135.6, 133.0, 132.3, 124.3, 121.0, 116.6, 114.7, 103.1, 73.5, 72.1, 68.6, 56.9, 56.3, 47.4, 47.1, 42.3, 42.1, 40.0, 39.7, 37.5, 35.8, 35.4, 35.3, 35.1, 34.5, 30.4, 28.7, 28.3, 27.0, 27.0, 23.7, 22.8, 20.4, 17.5, 13.9, 12.9.

[0187] Compound 4.26

[0188]

[0189] 1 1H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.47 (s, 2H), 7.73 (d, J = 2.5 Hz, 1H), 7.69 (d, J = 9.1 Hz, 1H), 7.40 (dd, J = 9.1, 2.5 Hz, 1H), 7.21 (dd, J = 8.6, 5.1 Hz, 2H), 7.12 (t, J = 8.6 Hz, 2H), 5.92 (s, 2H), 3.97 (s, 1H), 3.94 (s, 3H), 3.77 (s, 1H), 3.49 (td, J = 13.8, 5.3 Hz, 1H), 3.42 - 3.33 (m, 1H), 3.30 - 3.23 (m, 1H), 2.25 - 2.10 (m, 2H), 1.18 (d, J = 6.4 Hz, 3H), 0.88 (s, 3H), 0.71 (s, 3H);

[0190] 13 C-NMR (CD3OD & CDCl3, 100 MHz) δ 163.7 (d, J = 247.0 Hz), 156.5, 145.0, 140.8, 135.9, 134.1, 133.0 (d, J = 3.0 Hz), 131.0, 129.5 (d, J = 8.0 Hz), 124.9, 121.2, 117.2 (d, J = 22.0 Hz), 116.8, 114.8, 103.3, 73.6, 72.2, 68.6, 59.7, 56.3, 47.7, 47.2, 42.4, 42.3, 40.1, 39.8, 37.6, 35.9, 35.4, 35.3, 35.1, 30.5, 28.9, 28.2, 27.6, 27.2, 23.7, 22.9, 17.3, 12.9.

[0191] Compound 4.27

[0192]

[0193] 1 H-NMR (CD3OD & CDCl3, 400 MHz): δ 8.47 - 8.29 (m, 2H), 7.74 - 7.59 (m, 2H), 7.32 (dd, J = 9.0, 2.5 Hz, 1H), 7.14 (d, J = 7.9 Hz, 2H), 6.98 (d, J = 7.9 Hz, 2H), 6.02 - 5.70 (m, 2H), 3.91 (s, 1H), 3.87 (s, 3H), 3.71 (s, 1H), 3.43 (td, J = 13.8, 5.2 Hz, 1H), 3.36 - 3.10 (m, 2H), 2.26 (s, 3H), 2.17 - 2.01 (m, 2H), 1.11 (d, J = 6.2 Hz, 3H), 0.82 (s, 3H), 0.63 (s, 3H);

[0194] 13 C-NMR (CD3OD & CDCl3, 100 MHz) δ 156.2, 144.9, 140.6, 139.9, 135.8, 134.0, 132.7, 131.8, 130.8, 127.1, 124.6, 121.1, 116.5, 114.7, 103.2, 73.6, 72.1, 68.6, 60.4, 56.3, 47.6, 47.1, 42.2, 42.2, 40.0, 39.7, 37.4, 35.9, 35.3, 35.2, 34.9, 30.4, 28.7, 28.0, 27.6, 27.0, 23.7, 22.9, 21.3, 17.2, 12.9.

[0195] Example 3

[0196] The antibacterial activity of the steroidal carboline quaternary ammonium salt derivatives of formula I was determined through preliminary tests, and the MIC value of some of the antibacterial activities did not exceed 32 μg / mL. In this example, several compounds with superior activity were selected and further evaluated for biological activity.

[0197] In this example, the two-fold dilution method was used to determine the inhibitory activity of the steroidal carboline quaternary ammonium salt derivative of Formula I of the present invention against Ralstonia solanacearum, Methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus.

[0198] Specific methods:

[0199] Prepare the samples with the concentrations of 256, 128, 64, 32, 16, 8, 4, 2, 1 μg / mL, and prepare the concentration gradient solution of the positive control in the same way. Accurately pipette the diluted samples to be tested and 100 μL of the positive control into a 96-well plate, then take 50 μL of the calibrated bacterial solution and add it to the 96-well plate, and finally use sterile LB culture solution to calibrate the total volume of each well to 200 μL (at this time, the concentration gradient can be obtained as 128, 64, 32, 16, 8, 4, 2, 1, 0.5 μg / mL test concentration), and place it in a constant temperature incubator for 12 hours. Ampicillin sodium is used as the positive control, and LB culture solution containing 5‰ DMSO is used as the blank control, and three parallels are set at the same time. After the culture is completed, turbidity will appear in the wells with bacterial growth, and the concentration of the drug solution in the last well without bacterial growth is the MIC value of the sample. The results are shown in Table 1.

[0200] Table 1 Antibacterial activity MICs (μg / mL) of some compounds

[0201]

[0202] The results in Table 1 show that, with the antibacterial drugs ampicillin sodium and vancomycin as control drugs, the steroidal carboline quaternary ammonium salt derivatives (compounds 4.2, 4.8, 4.9, 4.15 and 4.26) showed good inhibitory activity against three pathogenic bacteria: Ralstonia solanacearum, Methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus.

[0203] Through this example, it can be preliminarily inferred that the antibacterial activity of the steroidal carboline quaternary ammonium salt derivative of formula I of the present invention is better than that of ampicillin sodium, and is equivalent to that of vancomycin, and has a prospect for further research and development.

[0204] The above is only a preferred specific implementation manner of the present invention, and the protection scope of the present invention is not limited thereto. Any simple change or equivalent replacement of the technical solution that can be obviously obtained by any technician familiar with the technical field within the technical scope disclosed in the present invention falls within the protection scope of the present invention.

Claims

1. A steroidal carboline quaternary ammonium salt derivative, characterized in that: The derivative has the following structure: Wherein, the substituent R1 represents hydrogen, hydroxyl, ester group, halogen; The substituents R2 and R3 represent hydroxyl, C1-C6 alkyl, hydroxyl-substituted C1-C6 alkyl, mono-substituted or poly-substituted aromatic group; The substituent R4 represents a C1-C6 alkyl group or a benzyl group containing various substituents; The substituent R5 represents hydrogen, methoxy or halogen.

2. The steroidal carboline quaternary ammonium salt derivative according to claim 1, characterized in that The substituent R4 is a C1-C6 straight-chain alkyl group, a C1-C6 branched-chain alkyl group, a monosubstituted or polysubstituted benzyl group, and a benzyl group substituted with various heteroatoms.

3. The steroidal carboline quaternary ammonium salt derivative according to claim 1, characterized in that The derivative has the following structure:

4. The method for preparing the steroidal carboline quaternary ammonium salt derivative according to any one of claims 1 to 3, characterized in that: The following steps are involved: Step 1: Select steroidal aldehyde compound 1 as the synthetic intermediate of each steroidal carboline quaternary ammonium salt derivative, and react with tryptamine derived from different substituents under the catalysis of acetic acid to generate target derivative compound 2; Step 2: Compound 2 is oxidized on palladium carbon to generate compound 3; Step 3: Compound 3 is reacted with chlorohydrocarbons of different substitutions to obtain compound 4.

5. Use of the steroidal carboline quaternary ammonium salt derivative according to any one of claims 1 to 3 in the preparation of antibacterial drugs.

6. The use according to claim 5, characterized in that: The antibacterial drug is a drug that inhibits the activity of Ralstonia solanacearum, methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus.

7. An antibacterial pharmaceutical composition, characterized in that: The invention comprises the steroidal carboline quaternary ammonium salt derivative according to any one of claims 1 to 3 and a pharmaceutically acceptable excipient.

8. The antibacterial pharmaceutical composition according to claim 7, characterized in that: The dosage form of the pharmaceutical composition is granules, tablets, pills, dragees, suppositories, capsules, sustained-release capsules, sustained-release tablets, suspensions or injections.

9. The antibacterial pharmaceutical composition according to claim 7, characterized in that: The excipients are pharmaceutical excipients for oral, enteral, parenteral or topical administration.

10. The antibacterial pharmaceutical composition according to claim 9, characterized in that: The auxiliary materials are water, magnesium stearate, talc, starch, organic acid, dextran or lipid.